+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of hepatic contrast enhancement with a hepatocyte-specific magnetic resonance imaging contrast agent (gadoxetic acid) in healthy dogs



Evaluation of hepatic contrast enhancement with a hepatocyte-specific magnetic resonance imaging contrast agent (gadoxetic acid) in healthy dogs



American Journal of Veterinary Research 76(3): 224-230



To determine, by means of MRI, the time to maximal contrast enhancement in T1-weighted images following IV administration of gadoxetic acid in healthy dogs and assess the impact of gadoxetic acid on the signal intensity of T2-weighted images. 7 healthy dogs. No hepatic abnormalities were detected during ultrasonographic examination. Each dog was anesthetized and positioned in dorsal recumbency for MRI. Transverse T1- and T2-weighted images of the liver were acquired prior to and following (at 5-minute intervals) IV injection of 0.1 mL of gadoxetic acid/kg. Signal intensity of the liver parenchyma was measured in 3 regions of interest in the T1- and T2-weighted images before and at various times point after contrast agent administration. Time versus signal-to-noise ratio curves were plotted to determine time to maximal contrast enhancement and contrast agent-related changes in signal intensity in T2-weighted images. Analysis of T1-weighted images revealed that mean ± SD time to maximal enhancement after gadoxetic acid injection was 10.5 ± 3.99 minutes. Signal intensity of T2-weighted images was not significantly affected by gadoxetic acid administration. No injection-related adverse effects were observed in any dog. Results indicated that gadoxetic acid can be used for hepatic MRI in healthy dogs and the resultant hepatic enhancement patterns are similar to those described for humans. Maximal contrast enhancement occurred between 10 and 15 minutes after contrast agent injection; thus, T2-weighted images may be obtained in the interval between injection and maximal enhancement for a more time-efficient clinical protocol.

(PDF emailed within 0-6 h: $19.90)

Accession: 057813570

Download citation: RISBibTeXText

PMID: 25710758

DOI: 10.2460/ajvr.76.3.224


Related references

Liver enhancement in healthy dogs after gadoxetic acid administration during dynamic contrast-enhanced magnetic resonance imaging. Veterinary Journal 235: 16-21, 2018

Liver enhancement in healthy dogs after gadoxetic acid administration during dynamic contrast-enhanced magnetic resonance imaging. Veterinary Journal 235: 16-21, 2018

A Hyaluronic Acid-Conjugated Gadolinium Hepatocyte-Specific T1 Contrast Agent for Liver Magnetic Resonance Imaging. Molecular Imaging and Biology 17(4): 497-503, 2016

Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. Journal of Magnetic Resonance Imaging 37(4): 903-908, 2013

A modular lymphographic magnetic resonance imaging contrast agent: contrast enhancement with DNA transfection potential. Journal of Medicinal Chemistry 40(25): 3992-3996, 1997

A nanocomplex system as targeted contrast agent delivery vehicle for magnetic resonance imaging dynamic contrast enhancement study. Journal of Nanoscience and Nanotechnology 10(11): 7545-7549, 2010

Practical use and pitfalls of hepatocyte-specific contrast agents (HSCAs) for pediatric hepatic and biliary magnetic resonance imaging. Abdominal Radiology (): -, 2016

Hepatocyte-specific contrast agent-enhanced magnetic resonance cholangiography: perioperative evaluation of the biliary tree. Radiologia Brasileira 50(6): 389-394, 2018

Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. Journal of Magnetic Resonance Imaging 31(2): 356-364, 2010

Magnetic resonance elastography as a predictor of insufficient liver enhancement on gadoxetic acid-enhanced hepatocyte-phase magnetic resonance imaging in patients with type C hepatitis and Child-Pugh class A disease. Investigative Radiology 47(10): 566-570, 2013

Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Arzneimittel-Forschung 43(8): 927-931, 1993

A LC-MS/MS method to evaluate the hepatic uptake of the liver-specific magnetic resonance imaging contrast agent gadoxetate (Gd-EOB-DTPA) in vitro and in humans. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 891-892: 20-26, 2012

Imaging of murine liver tumor using microCT with a hepatocyte-selective contrast agent: accuracy is dependent on adequate contrast enhancement. Journal of Surgical Research 119(1): 41-45, 2004

Evaluation of a nitroxyl fatty acid as liver contrast agent for magnetic resonance imaging. Magnetic Resonance In Medicine. 30(5): 592-599, 1993

Hepatocyte-specific magnetic resonance imaging contrast agents. Hepatology 53(2): 678-682, 2011